Phaseline

Companies › Impact Therapeutics

Impact Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 3; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
IMP4297
PARP inhibitor
PARP1, PARP2Phase 3Ovarian Cancer–
IMP9064
DNA-PKcs inhibitor
–Phase 1Solid TumorDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04169997IMP4297Phase 3Ovarian CancerOncologyMar 2023
NCT05269316IMP9064Phase 1Solid TumorOncologyDec 2026

Targets

PARP1 (1) PARP2 (1)

Companies with the same targets

AstraZeneca Merck & Co. (MSD) Pfizer Johnson & Johnson (Janssen) GSK Eikon Therapeutics BeiGene pharmaand Allarity Therapeutics Boryung Pharmaceutical

Companies built like this

VIVUS Allarity Therapeutics Clarity Pharmaceuticals TYK Medicines TransThera Sciences (Nanjing)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.